Potential First-in-Class, Targeted Therapy for Myasthenia Gravis Potential First-in-Class, Targeted Therapy for Myasthenia Gravis

Efgartigimod is linked to clinically meaningful improvements in strength and quality of life in patients with generalized myasthenia gravis, the phase 3 ADAPT trial shows.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news